KemPharm (KMPH) Announces Earnings Results

KemPharm (NASDAQ:KMPH) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.46), Fidelity Earnings reports.

Shares of NASDAQ KMPH opened at $1.20 on Thursday. KemPharm has a fifty-two week low of $1.15 and a fifty-two week high of $7.15. The stock has a market cap of $32.54 million, a PE ratio of -0.48 and a beta of 1.63.

An institutional investor recently raised its position in KemPharm stock. Geode Capital Management LLC lifted its holdings in shares of KemPharm Inc (NASDAQ:KMPH) by 136.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 171,047 shares of the specialty pharmaceutical company’s stock after acquiring an additional 98,775 shares during the period. Geode Capital Management LLC owned 0.65% of KemPharm worth $304,000 at the end of the most recent reporting period. Institutional investors own 34.30% of the company’s stock.

Separately, ValuEngine lowered KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $10.75.

ILLEGAL ACTIVITY NOTICE: “KemPharm (KMPH) Announces Earnings Results” was originally reported by Rockland Register and is owned by of Rockland Register. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://rocklandregister.com/2019/05/16/kempharm-kmph-announces-earnings-results.html.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Featured Story: Investing in Growth Stocks

Earnings History for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.